AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05552157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Remternetug)
Description: Administered as subcutaneous injection of placebo every 12 weeks
Study NCT06447441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Enteral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days within 96 hours after ICU admission
Study NCT05665361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).
Study NCT05665361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbocicilib
Description: Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
Study NCT06428955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT LUCIA 621P
Description: The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
Study NCT03963583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROIC
Description: The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals.
Study NCT05468138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX
Description: Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Study NCT05468138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Study NCT05468138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
Study NCT05468138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
Study NCT06293079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
Study NCT06293079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
Study NCT06075849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB101
Description: Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator.
Study NCT06328608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102 1 mg/kg every two weeks
Description: Drug: PRX-102 1 mg/kg every two weeks
Study NCT06030128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core stabilization exercise
Description: All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
Study NCT04688515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition program developed using positive deviance approach
Description: It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
Study NCT04817514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder rehabilitation exercises and aerobic exercises
Description: SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines.
Study NCT04670315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Telematic evaluation of motor function
Description: Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
Study NCT06037083 — intervention group
Intervention type: DEVICE
Intervention: Oxygen saturation probe
Description: The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
Study NCT06037083 — intervention group
Intervention type: DEVICE
Intervention: Near infrared spectroscopy sensors
Description: The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
Study NCT06037083 — intervention group
Intervention type: DEVICE
Intervention: Electrical impedance tomography
Description: The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~* From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~* Between 24 and 48 hours post extubation (total 3 hours)~* Between 72 and 96 hours post extubation (total 3 hours)
Study NCT05685602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy
Study NCT05685602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04680780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Patients will follow a classical ketogenic diet for 3 months
Study NCT05685602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT05685602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Given PO
Study NCT05685602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT05685602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05685602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT05685602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study NCT05685602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study NCT06470451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
Study NCT06470451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
Study NCT05906095 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LOCK Falls Program
Description: The LOCK Falls Program helps multi-disciplinary frontline staff teams (nursing, physician, housekeeping, physical therapy, etc.) work together to identify and discuss risk factors for falling and use rapid-cycle QI techniques to pilot and monitor their actions to reduce resident falls.
Study NCT04631302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Mindful
Description: Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises.
Study NCT04631302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light exercise course
Description: The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness.
Study NCT05498974 — intervention group
Intervention type: OTHER
Intervention: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Description: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Study NCT04908761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block
Description: Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
Study NCT04908761 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
Study NCT06267274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic Solution, 0.01%
Description: 1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
Study NCT06267274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Description: 1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
Study NCT04746716 — intervention group
Intervention type: OTHER
Intervention: Phone call
Description: Phone call to the patient to complete quality of life scales
Study NCT04680780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-days water-fasting
Description: Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
Study NCT04680780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (>3 l/day) which is considered beneficial in ADPKD.
Study NCT06432725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JUNTOS
Description: HIV test counselor and Latino MSM participants will be given access to the JUNTOS website/app, which shows information about local HIV and ancillary services. HIV test counselor participants will also be given access to a training video explaining how to use the JUNTOS website/app. HIV test counselors are encouraged to use the website/app for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the website/app to locate HIV and ancillary services as needed.
Study NCT06432725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral Sheet
Description: HIV test counselor and Latino MSM participants will be given access to referral sheet, which is a list of local HIV and ancillary services. HIV test counselors are encouraged to use the referral sheet for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the referral sheet to locate HIV and ancillary services as needed.
Study NCT06216028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Aspirate Concentrate
Description: Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)
Study NCT04917393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRF System Multi-organ Denervation
Description: If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
Study NCT04917393 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Procedure
Description: If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
Study NCT04862806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 serology
Description: Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value > 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value >15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value >1.1; range 1.1-10).
Study NCT05991687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-home drug disposal pouch
Description: Will receive a drug disposal pouch to inactivate leftover prescription opioids for disposal after surgery.
Study NCT05991687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mail-in prepaid envelope
Description: Will receive a prepaid envelope to mail leftover prescription opioids for disposal after surgery
Study NCT04875585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy with Pembrolizumab/Lenvatinib
Description: Neoadjuvant therapy for 6 weeks
Study NCT05318378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BIXAM
Description: Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
Study NCT05318378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BIXAM
Description: Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
Study NCT06132399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: META QUEST 3 virtual reality glasses
Description: The RESET virtual reality software will be integrated into META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US) by DYNAMICS.
Study NCT06132399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan)
Description: This group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the Sports package games.
Study NCT06132399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The UC intervention consists of 3 sessions/week of 90' of physical therapy and occupational therapy conducted by a physiotherapist and an occupational therapist.
Study NCT05587218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-production
Description: After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
Study NCT05587218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-production
Description: After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
Study NCT04616027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20 mg
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
Study NCT05045833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 Delayed Release Capsule
Description: Oral administration (by mouth)
Study NCT06184399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1.5 mg ODT
Description: Oro-dispersible tablets of 1.5 mg ivermectin
Study NCT06184399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 3 mg Oral Tablet
Description: Tablets of 3 mg ivermectin
Study NCT06184399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole
Study NCT06184399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole
Study NCT06184399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole
Study NCT06184399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVM ODT
Description: Placebo for ivermectin ODT
Study NCT06051760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NV-001
Description: NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
Study NCT04609540 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Dual anti-HER2 therapy
Study NCT05976490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Support Intervention
Description: Information guide and four one-on-one coaching sessions
Study NCT05976490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual supportive care
Description: Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician
Study NCT04875585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: surgical resection of primary tumor and lymph-node-dissection.
Study NCT04875585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Treatment Phase
Description: Adjuvant treatment with 15 cycles of Pembrolizumab
Study NCT05078502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: One capsule of vitamin D3(40000IU) weekly for 8 weeks
Study NCT05078502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: One capsule of vitamin D3(40000IU) weekly for 8 weeks
Study NCT06256198 — intervention group
Intervention type: OTHER
Intervention: measurement of serum lactate and procalcitonin and PCO2 gap
Description: measurement of serum lactate, procalcitonin and PCO2 gap
Study NCT05695534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR educational video
Description: Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.